Preventive effect of hydrazinocurcumin on carcinogenesis of diethylnitrosamine-induced hepatocarcinoma in male SD rats.
The purpose of the present study was to evaluate the preventive effects of hydrazinocurcumin (HZC) on diethylnitrosamine (DEN)-induced hepatocarcinogenesis in a male Sprague Dawley (SD) rat model. One hundred and twenty male SD rats used in this study were divided into six groups. Those receiving DEN with curcumin (CUR) or HZC were studied compared with the DEN-alone group. The study demonstrated that DEN induced severe histological and immunohistochemical changes in liver tissues, significantly increasing the levels of liver marker enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyltransferase (GGT) and total bilirubin level (TBL)). The hepatocarcinoma incidences were 100.0%, 36.7% and 20.0% in the DEN-alone, DEN-CUR and DEN-HZC groups, respectively. Although macroscopic and microscopic features suggested that both CUR and HZC were effective in inhibiting DEN- induced hepatocarcinogenesis, HZC was exerted a stronger influence. Immunohistochemical analysis with PCNA demonstrated significantly differences among the groups (all P < 0.05). Taken together, the results suggested application of CUR and HZC could prevent the occurrence of carcinogenesis and HZC may be a more potent compound for prevention of DEN-induced hepatocarcinogenesis in rats than CUR.
Department of Hepatobiliary Surgery, The First Affilliated Hospital, Hebei Medical University, Shijiazhuang, China E-mail : zhaoweili-88@hotmail.com.
Ji-An
JA
Zhao
Li
L
Peng
Cui-Zhi
CZ
Geng
Yue-Ping
YP
Liu
Xu
X
Wang
Hui-Chai
HC
Yang
Shi-Jie
SJ
Wang
D000410:Alanine Transaminase / Q000378:metabolism; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D001219:Aspartate Aminotransferases / Q000378:metabolism; D063646:Carcinogenesis / Q000187:drug effects* / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced* / Q000188:drug therapy* / Q000378:metabolism; D003474:Curcumin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004052:Diethylnitrosamine / Q000009:adverse effects*; D006834:Hydrazines / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008111:Liver Function Tests / Q000379:methods; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000188:drug therapy* / Q000378:metabolism; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D005723:gamma-Glutamyltransferase / Q000378:metabolism
D006834:Hydrazines; C475807:hydrazinocurcumin; D004052:Diethylnitrosamine; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D003474:Curcumin